TELA · XBRL financial data

TELA Bio financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TELA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	18,213	29,463	41,418	58,453	69,300	80,275
Gross profit	11,234	18,813	27,044	40,112	46,488	54,341
Research and development	4,255	6,743	8,937	9,619	8,813	9,220
General and administrative	10,143	12,459	13,862	14,887	14,722	15,694
Total operating expenses	36,509	48,264	66,051	84,187	88,183	88,096
Operating income (loss)	(25,275)	(29,451)	(39,007)	(44,075)	(34,115)	(33,755)
Interest expense	3,564	3,597	4,051	5,223	5,290	5,245
Other income (expense)	45	(228)	(10)	2,634	1,420	1,287
Income tax expense (benefit)	—	—	—	—	(144)	230
Net income (loss)	(28,794)	(33,276)	(44,296)	(46,664)	(37,841)	(38,831)
Earnings per share, basic USD per share	(2.23)	(2.30)	(2.72)	(2.04)	(1.33)	(0.83)
Earnings per share, diluted USD per share	(2.23)	(2.30)	(2.72)	(2.04)	(1.33)	(0.83)
Weighted average shares, basic thousands of shares	12,934	14,473	16,268	22,869	28,526	46,948
Weighted average shares, diluted thousands of shares	12,934	14,473	16,268	22,869	28,526	46,948

Fiscal years (TELA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	74,394	43,931	42,019	46,729	52,670	50,845
Short-term investments	0	—	—	—	—	—
Inventory	3,907	7,658	11,792	13,162	12,781	11,016
Prepaid and other current assets	2,241	3,232	2,015	2,098	2,522	3,373
Total current assets	83,225	59,055	62,447	71,726	78,071	75,581
Property and equipment, net	626	1,186	1,682	1,984	2,341	2,226
Right-of-use asset	—	—	1,227	1,954	1,738	1,502
Total assets	86,458	62,544	67,855	78,048	86,570	81,418
Accounts payable	652	2,414	1,534	1,667	2,147	2,309
Accrued liabilities	5,953	8,161	10,869	15,300	13,451	15,666
Total current liabilities	6,605	10,575	12,403	16,967	15,598	17,975
Long-term debt	—	—	39,916	40,515	41,124	55,653
Lease liability, non-current	—	—	1,200	1,700	1,400	—
Total liabilities	37,432	42,446	53,550	59,167	58,112	75,105
Accumulated deficit	(196,653)	(229,929)	(274,225)	(320,889)	(358,730)	(397,561)
Total stockholders' equity	49,026	20,098	14,305	18,881	28,458	6,313
Total liabilities and equity	86,458	62,544	67,855	78,048	86,570	81,418
Common shares outstanding (cover page) thousands of shares	14,440	14,552	19,217	24,650	39,551	44,740

Fiscal years (TELA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(28,794)	(33,276)	(44,296)	(46,664)	(37,841)	(38,831)
Stock-based compensation	2,058	3,661	3,989	5,032	4,362	3,796
Net cash from operating activities	(24,456)	(30,432)	(40,748)	(40,857)	(41,595)	(28,219)
Purchases of property and equipment	167	627	872	611	989	448
Net cash from investing activities	9,122	(627)	(1,872)	(599)	4,451	846
Proceeds from issuing common stock	34	—	34,400	46,341	—	—
Proceeds from long-term debt	—	—	40,000	—	—	—
Repayments of long-term debt	—	—	30,000	—	—	42,420
Net cash from financing activities	44,409	585	40,852	46,267	43,057	25,750
Net change in cash	29,092	(30,463)	(1,912)	4,975	5,941	(1,840)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
enVVeno Medical	2,585	not reported	(3,178)*	694,826	5.6 quarters	Q3 FY26 10-QSep 30, 2026
Carlsmed	46,244	not reported	(7,358)*	27.3M	9.5 quarters	Q2 FY26 10-QJun 30, 2026
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Lucid Diagnostics	33,404	not reported	(11,297)*	203.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Sensus Healthcare	15,186	2,290	(3,133)*	16.5M	4.8 quarters	Q2 FY26 10-QJun 30, 2026
Shoulder Innovations	24,460	17,175	(7,392)*	20.8M	13.4 quarters	Q2 FY26 10-QJun 30, 2026
Accuray	40,623	100,919*	2,427*	119.4M	—	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.